Ever wanted to meet the who’s who of Precision Oncology?

James H. Doroshow
Deputy Director for Clinical and Translational Research, NCI

Carl H. June
CAR T-cell therapy inventor

Josep Tabernero
President ESMO

Richard L. Schilsky
Chief Medical Officer ASCO

Cornelius Schmaltz
Head of Unit, Health Research Strategy, Directorate General for Research and Innovation, European Commission

Ellen V. Sigal
Chair and Founder of Friends of Cancer Research

WIN Symposium 2018 is endorsed by:

ESO_2011 v2
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.

WIN Symposium 2018 Program

Organizing Committee chairs:

John Mendelsohn
Chairman WIN Consortium
University of Texas MD Anderson Cancer Center (UT-MDACC), USA

Razelle Kurzrock
WIN Head of Clinical Trials Committee
Precision Medicine Center UC San Diego, USA


Lisa Hutchinson
Foundation for World Health (FWH), UK, WIN Consortium

Chang-Sik Yu
ASAN Medical Center Cancer Institute, Korea

Brian Leyland-Jones
McKeenan Avera Cancer Center, USA

Vladimir Lazar
WIN Consortium, France

Amir Onn
Chaim Sheba Medical Center, Israel

Catherine Bresson
WIN Consortium, UK

Richard L. Schilsky
American Society of Clinical Oncology (ASCO), USA

We are excited to celebrate our 10-year anniversary at the WIN Symposium 2018 in Paris, France! The following themes will be addressed:

  • The challenges of building real cooperation to implement Precision Oncology Programs: A long and winding Road
  • The next frontier of therapeutics in newly diagnosed patients: Standard of care or modern biomarker driven precision oncology?
  • Disruptive concepts and clinical trials shifting the paradigm of Precision Oncology
  • New concepts and therapeutics avenues in Precision Oncology
  • The regulatory challenges of a new model of drug development – The combination of targeted therapies
  • 10th year of the WIN Symposium in the era of Modern Oncology

The WIN Symposium 2018 will gather the most renown scientists in the world, including:

Mary Beattie
Senior Medical Director, Precision Medicine, Genentech, USA

James H. Doroshow
Deputy Director for Clinical and Translational Research, National Cancer Institute (NCI), USA

Laura Esserman
Professor of Surgery and Radiology, University of California San Francisco (UCSF), USA

Leroy Hood
President Institute for Systems Biology, USA

Carl H. June
Inventor of CAR T-cell therapies, 2017 David A. Karnofsky Memorial Award ASCO, Professor, Perelman School of Medicine, USA

Razelle Kurzrock
Senior Deputy Director for Clinical Science, Center for Personalized Cancer Therapy, UC San Diego, USA

Francesco De Lorenzo
President, European Cancer Patient Coalition (ECPC), Belgium

Jean-François Martini
Senior Director, Translational Oncology, Global Product Development-Oncology, Pfizer Inc., USA

John Mendelsohn
Past President, University of Texas MD Anderson Cancer Center, Director of Khalifa Institute for Personalized Cancer Therapy, USA

Amir Onn
Head Department of Pulmonary Medicine and Pulmonary Oncology, Sheba Medical Center, Israel

Harvey I. Pass
Thoracic and Cardiac Surgeon, NYU Langone Health, USA

Eric Rubin
Senior Vice President and Therapeutic Area Head, Oncology Early Development, Merck, USA

Richard L. Schilsky
Senior Vice President and Chief Medical Officer ASCO, USA

Cornelius Schmaltz
Head of Unit, Health Research Strategy, Directorate General for Research and Innovation, European Commission, Belgium

Ellen V. Sigal
Chair and Founder of Friends of Cancer Research, USA

Jean-Charles Soria
Senior Vice President, Head of Oncology Innovative Medicines, MedImmune, USA

Josep Tabernero
ESMO President, Director Vall d’Hebron Institute of Oncology (VHIO), Spain

Bernadette Toner
Chief Executive Officer, GenomeWeb, USA

John Wilden
Co-Founder and Trustee, Foundation for World Health (FWH), UK

Yosef Yarden
Israel Prize in Life Science Research, Professor, Weizmann Institute of Science, Israel


For more information about registration, abstract management and your trip to Paris, please click on the tabs below.


WIN 2018 will be held at Hotel Novotel Paris Tour Eiffel , 61 Quai de Grenelle, 75015 Paris, France.

The venue is located in the heart of Paris on the borders of the Seine river and a short distance from the Eiffel Tower. The hotel is also close to the Champs-Elysées, the Louvre and Notre-Dame.

Hotel accommodation

WIN 2018 delegates may book hotel accommodation at the venue at the special delegate rate, giving them the benefit of having the symposium facilities and their hotel room under one roof. Hotel accommodation at the Hotel Novotel Paris Tour Eiffel can be booked via a special booking site. Please click here for the official booking website

WIN Symposium dinner

The Monday evening dinner will be held at le Pavillon Dauphine, which is ideally located nearby the Avenue des Champs-Elysées.

Le Pavillon Dauphine was built on the edge of the Bois de Boulogne, at the bottom of Avenue de l’Impératrice, now known as Avenue Foch, at the beginning of the last century. It is surrounded by gardens and the prestigious setting is ideal for fostering communication.

Monday June 25, 2018 | 18.30 – 22.30 hrs
Le Pavillon Dauphine
Regular delegates: €100,- per ticket / Accompanying persons: €150,- per ticket

Transportation to/from le Pavillon Dauphine is included in the costs of the dinner.



Online registration is now open.

Registration fees (in €)Until March 31April 1 until June 24As of June 24 and on-site
Students, residents in training
Student/resident status to be documented


For group registration, contact the Symposium Secretariat.


Cancellation of registration has to be made in writing to the Symposium Secretariat. If a cancellation is received before or on June 19, 2018, reimbursement of the registration fee, minus €100,- handling charges, will be made. After this date, or if registrants fail to attend the symposium for any reason whatsoever, regrettably no refund can be made.

Scholarships and travel grants

Unfortunately, no scholarships, travel grants or waiver of registration fees can be provided to any WIN 2018 delegate. Students and residents in training may register at strongly reduced fees, provided they can document student/resident status.

Press policy

Representatives of the press and media agencies with media credentials are welcome to attend the WIN 2018 Symposium. Contact the Symposium Secretariat for details of media registration.

By registering as media representatives for WIN 2018, journalists, press photographers, film crews and other members of the press accept that they must comply with the WIN 2018 Press Policy. Failure to do so may result in the immediate withdrawal of press registration.

Picture taking, audio/video recording and/or filming at the WIN 2018 venue without prior permission of the WIN 2018 Symposium organizers are prohibited. Requests for interviews of speakers or faculty should be sent to the Symposium Secretariat.

Media partnership

The WIN 2018 Symposium Committee is open to discussing media partnerships with media active in the field of cancer and precision medicine. Contact the Symposium Secretariat to post your interest in a media partnership.

Abstract submission

Online abstract submission is now open. All accepted abstracts will be scheduled for presentation in poster viewing sessions not overlapping with other elements of the program. Please prepare your abstract according to the WIN 2018 abstract guidelines.

Abstracts within one of the following topics are welcome:

  • Bioinformatics
  • Biomarkers (prognostic and predictive)
  • Cancer prevention
  • Clinical trial design
  • Diagnostics
  • Drug design and discovery
  • Drug resistance and modifiers
  • Early diagnosis of cancer
  • Experimental therapies – clinical
  • Experimental therapies – preclinical
  • Genetics, genomics and proteomics
  • New combinations (agents and modalities)
  • New treatment strategies
  • Patient reported outcomes
  • Preclinical test models

Important deadlines:

  • May 30, 2018: Deadline abstract submission, withdrawal and change of abstract content
  • June 8, 2018: Notification of abstract scheduling/rejection to submitting author
  • June 13, 2018: Deadline registration for presenting authors

European CME credits

The WIN Symposium 2018, Paris, France, 25/06/2018-26/06/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 13 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Sponsoring the event

WIN Consortium, organizer of the WIN Symposium series, invites financial support from corporations, foundations, and other organizations to help defray the costs of organizing WIN 2018. Various attractive benefits are available to sponsoring and supporting entities. All sponsoring contributions will be considered unrestricted educational grants towards the WIN Symposium 2018.

Educational grants for which the donator receives no specific benefits other than grant acknowledgements in association with WIN 2018 are also welcome.

If you are interested in discussing a sponsorship arrangement, or if you have other suggestions for a specific sponsorship arrangement, please contact the WIN Symposium 2018 Secretariat.

Symposium WIN2017 Key speakers

    Interviews with WIN 2017 speakers by Ecancer

    To watch all videos with the WIN 2017 speakers please click here »

    Dr. Richard L. Schilsky
    Chairman Scientific Advisory Board WIN

    Prof. Jack Lee
    University of Texas MD Anderson Cancer Center, USA

    Prof. Martine J. Piccart-Gebhart
    Director of Medicine, Institute Jules Bordet, Brussels, Belgium

    WIN 2017 Symposium Program

    The WIN 2017 Symposium program elaborated the theme ‘Expediting Global Innovation in Precision Cancer Medicine’  in six plenary sessions, divided over two days of meetings. The program was supplemented by poster viewing sessions, not overlapping with the plenary sessions, and a plenary poster awarding ceremony.

    José Baselga
    Memorial Sloan Kettering, USA

    Keynote Opening Lecture
    Genomic-driven Clinical Studies in Breast Cancer

    René Bernards
    NKI, The Netherlands

    Synthetic lethality as a basis to select drug combinations in animal models and in cancer patients

    Martine J. Piccart-Gebhart
    Institut Jules Bordet, Belgium

    Biomarker Research in Breast Cancer: A Journey into the Desert

    Daniel F. Hayes
    University of Michigan Comprehensive Cancer Center, USA

    Incorporating Liquid Biopsies into Clinical Trials to Select and Monitor Participants

    WIN 2017 Organizing Committee
    Chairs: Gerald Batist (Canada) and Thomas Tursz (France)
    Members: Lisa Hutchinson (UK), Razelle Kurzrock (USA), Brian Leyland-Jones (USA), John Mendelsohn (USA), Amir Onn (Israel), Richard L. Schilsky (USA), Josep Tabernero (Spain), Vladimir Lazar (France), Catherine Bresson (France)

    Monday June 26, 2017


    8:30 – 8:40

    8:40 – 9:10

    Welcome and opening remarks
    John Mendelsohn, University of Texas MD Anderson Cancer Center, USA

    Keynote opening lecture: Genomic-driven Clinical Studies in Breast Cancer
    José Baselga, Memorial Sloan Kettering, USA


    9:10 – 9:30

    9:30 – 9:50

    9:50 – 10:10

    10:35 – 10:55

    10:55 – 11:40

    Fit for Purpose: Using Biomarkers and Diagnostics in clinical trials, to Impact Personalized Care
    Laura Esserman, University of California San Francisco, Carol Franc Buck Breast Care Center, USA

    Shifting the Clinical Trial Paradigm to Keep Pace with Rapidly Changing Cancer Biology
    Donald A. Berry, University of Texas MD Anderson Cancer Center, USA

    Bayesian Adaptive Designs for Precision Medicine: Promise, Progress, and Challenge
    J. Jack Lee, University of Texas MD Anderson Cancer Center, USA

    Redesigning Clinical Trials in the Era of Precision Medicine: What the Science Demands
    Razelle Kurzrock, University of California, San Diego Moores Cancer Center, USA

    Open Forum and Debate:  New trends in clinical trial design
    Moderated by Razelle Kurzrock, University of California, San Diego Moores Cancer Center, USA and Brian Leyland Jones, Avera Cancer Institute, USA


    11:45 – 12:10

    12:10 – 12:35

    12.35 – 13.00

    Toward full integration of patient-related data into drug and biomarker discovery: a retro-translational process?
    Patrice P. Denèfle, Institut Roche for Research & Translational Medicine, France

    Chromatin dynamics – epigenetic parameters and cellular fate
    Geneviève Almouzni, Institut Curie, France

    DNA damage response pathway inhibition – a pipeline and the phase 1 experience
    Giorgio Massimini, Merck KGaA, Germany


    14:00 – 14:25

    14:25 – 14:50

    14:50 – 15:15

    15:40 – 16:05

    16:05 – 16:30

    16:30 – 16:55

    16:55 – 17:15

    17.15 – 18.00


    New biomarkers for response to immunotherapy
    Antoni Ribas, University of California Los Angeles, USA

    Precision medicine enabled histology agnostic development of immune-oncology agents
    Roy D. Baynes, Merck Sharpe & Dohme, USA

    The Complex Challenges of Stratifying Patients for Immunotherapy
    Steve Anderson, Covance, USA

    Apoptosis, cancer and immunity; therapeutic implications
    Guido Kroemer, Gustave Roussy, France

    Patient-specific peptide vaccines
    Hans-Georg Rammensee, University of Tübingen, Germany

    Open Forum and Debate:  Place of immunotherapy approaches in precision cancer care
    Moderated by Antoni Ribas, University of California Los Angeles, USA and Jean-Yves Blay, Centre Léon Bérard, France

    Awarding ceremony best-poster awards

    Welcome reception and poster viewing

    Symposium dinner cruise

    Tuesday June 27, 2017


    8:30 – 8:55

    8:55 – 9:20

    9:20 – 9:45

    9:45 – 10:10

    Novel models to personalize cancer therapeutics
    Olli Kallioniemi,  Science for Life Laboratory, Karolinska Institutet, Stockholm & Institute for Molecular Medicine Finland (FIMM), Finland

    Omics Convergence (Proteogenomics) in Cancer Research: New Opportunities in Cancer Biology and Precision Medicine
    Henry Rodriguez, National Cancer Institute, USA

    Genomic analysis of childhood tumors; biological and therapeutic implications
    Peter Lichter, DKFZ, Germany

    Cancer Genome Sequencing in a Multi-Institutional Clinical Setting “The MASTER Study of the German Cancer Consortium”
    Stefan Fröhling, DKFZ, Germany


    10:40 – 11:05

    11:05 – 11:30

    11:30 – 11:55

    11:55 – 12:20

    Biomarker Research in Breast Cancer: A Journey into the Desert
    Martine J. Piccart-Gebhart, Institut Jules Bordet, Belgium

    Prognostic, predictive and clinically relevant biomarkers – A pharma perspective
    Jean-François Martini, Pfizer Inc., USA

    Augmented Intelligence in the clinical set of Precision Oncology – A IBM Watson perspective
    Vanessa V. Michelini, IBM Watson Health, USA

    Combining immune-based therapies with TKIs in melanomas
    Caroline Robert, Gustave Roussy, France


    13:40 – 14:05

    14:05 – 14:30

    14:30 – 14:55

    14:55 – 15:20

    15:20 – 15:45

    Synthetic lethality as a basis to select drug combinations in animal models and in cancer patients
    René Bernards, NKI, The Netherlands

    Incorporating Liquid Biopsies into Clinical Trials to Select and Monitor Participants
    Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, USA

    Molecular medicine in lung cancer
    Reinhard Büttner, University Hospital of Cologne, Germany

    The INFORM program – personalizing pediatric oncology on a population-based level in Germany
    Stefan Pfister, DKFZ, Germany

    Genomic Predictors of Treatment Response in Prostate Cancer: A New Era
    Robert G. Bristow, Princess Margaret Cancer Centre, Canada


    16:10 – 16:45

    Challenges of real world implementation of Precision Medicine, and implications for other diseases

    Lisa Hutchinson, Nature Publishing Group, UK
    Thomas Tursz, Fondation ARC, France

    Andrea Califano, Columbia University, USA
    Martine J. Piccart-Gebhart, Institut Jules Bordet, Belgium
    Richard L. Schilsky, ASCO, USA
    Francesco De Lorenzo, ECPC, Belgium


    16:45 – 17:10

    Systems Medicine, Big Data and Scientific Wellness are transforming Healthcare
    Leroy Hood, Institute for Systems Biology, USA

    Report WIN 2015 Symposium

    For an extensive meeting report by Dr. Richard L. Schilsky visit ecancer. Below is a brief summary report for your quick orientation.

    The WIN 2015 Symposium, a two-day symposium on precision cancer medicine offered by WIN Consortium, attracted delegates from 36 countries worldwide. The overarching theme this year was Novel targets, innovative agents, advanced technologies: A WINning strategy? This theme was elaborated in various plenary sessions with over 25 internationally renown speakers, a round table of global pharma and academic experts on Overcoming resistance through combined therapies, moderated by Richard L. Schilsky, ASCO’s Chief Medical Officer and WIN Consortium’s Scientific Advisory Board chair, and poster presentations. Many presentations (PDF) can be viewed on this website.

    James Allison, presenter of a keynote lecture

    James Allison, presenter of a keynote lecture

    Keynote lectures were presented by John Mendelsohn, Chairman, WIN Consortium, on The Era of Precision Cancer Medicine: A worldwide effort and challenge, James Allison, The University of Texas MD Anderson Cancer Center, on Targeting immune mechanisms,Andrea Califano, Columbia University, on  A systems biology approach to precision cancer medicine, James Doroshow, U.S. National Cancer Institute (NCI) on A perspective on NCI’s strategy and trials, and Francesco Pignatti, European Medicines Agency (EMA) on The EMA adaptive pathways approach to improve timely access for patients to new medicines. 

    Richard L. Schilsky, ASCO’s Chief Medical Officer and Chairman of WIN Consortium’s SAB, moderated a lively round-table discussion of pharma and academic experts on Overcoming resistance through combined therapies.

    WIN Consortium encourages the submission of high-quality abstracts on precision cancer medicine by awarding best-poster awards to a few posters presented at the annual WIN Symposium.


    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

    What experts said about the WIN 2017 Symposium

    John Mendelsohn
    Chairman of the WIN Consortium
    What is the WIN Consortium?

    Vladimir Lazar
    Chief Scientific and Operating Officer, WIN Consortium
    Global horizons of the WIN Consortium

    I’m waging war on Cancer after it killed my soninjection.jpg

    When my son died of cancer I decided to wage war on the disease myself. Precisely because cancer is so complex, giving patients one targeted therapy does not make much biological sense – that’s why we need to test new treatments urgently.

    –  Catherine Bresson, Director, Operational Team of the WIN Consortium.

    Please read the full article at independent.co.uk.